Tulus Ariyadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tulus Ariyadi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Afifah Khairunnisa
Department of Medical Laboratory Technology, Faculty of Health and Nursing Universitas Muhammadiyah Semarang Semarang Indonesia
2 shared publications - Ana Hidayati Mukaromah
Universitas Muhammadiyah Semarang
1 shared publication - Andri Sukeksi
Department of Medical Laboratory Technology, Faculty of Health and Nursing Science, Universitas Muhammadiyah Semarang, Semarang, 50273, Indonesia
1 shared publication - Annisa Nurul Hikmah
Universitas Muhammadiyah Semarang
1 shared publication - Asyiah Asyiah
Universitas Muhammadiyah Semarang
1 shared publication - Budi Santosa
Universitas Muhammadiyah Semarang
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 2987105
Emerging Multidrug‐Resistant Bacteria in Indonesian Neonatal Patients: Prevalence and Antimicrobial Resistance Profiles From Clinical Samples
Background: Neonatal sepsis poses a serious health challenge, especially with the increasing prevalence of multidrug‐resistant (MDR) bacteria among Indonesian neonates. This study examines the occurrence of MDR bacteria in clinical samples from neonates and analyzes their resistance patterns to enhance treatment strategies. Methods: From January 2022 to December 2024, a total of 223 bacterial isolates were gathered from neonatal patients with infections at Kanjeng Raden Mas Tumenggung Wongsonegoro Hospital in Semarang, Indonesia. The identification process commenced with Gram staining and assessment of colony morphology preceded by antibiotic susceptibility testing utilizing the VITEK2 Compact systems. Results: The study findings revealed a notable prevalence of MDR infections. Fecal samples accounted for 29.15% of the samples analyzed, with 63.1% exhibiting MDR characteristics. Blood samples, representing 24.66% of the samples, displayed a concerning MDR rate of 83.6%. Similarly, urine samples (24.66%) showed a MDR rate of 50.9%, while sputum samples (10.76%) presented a striking MDR classification of 91.7%. Key MDR rates were identified in Escherichia coli (45.6%), Staphylococcus spp. (70.4%), Klebsiella pneumoniae (71.9%), Acinetobacter spp. (63.6%), and Pseudomonas aeruginosa (100%). The overall prevalence of MDR infections was calculated at 66.40%, with significant resistance observed towards ampicillin (over 80%) in gram‐negative bacteria and benzylpenicillin (over 90%) in gram‐positive bacteria, particularly Staphylococcus spp. Conclusion: The findings underscore the urgent need for effective strategies to combat MDR infections in healthcare settings, emphasizing enhanced antibiotic management, tailored treatment protocols, and a more holistic and systematically structured research strategy for neonatal units in Indonesia.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 2987105
Open AccessEmerging Multidrug‐Resistant Bacteria in Indonesian Neonatal Patients: Prevalence and Antimicrobial Resistance Profiles From Clinical Samples
Background: Neonatal sepsis poses a serious health challenge, especially with the increasing prevalence of multidrug‐resistant (MDR) bacteria among Indonesian neonates. This study examines the occurrence of MDR bacteria in clinical samples from neonates and analyzes their resistance patterns to enhance treatment strategies. Methods: From January 2022 to December 2024, a total of 223 bacterial isolates were gathered from neonatal patients with infections at Kanjeng Raden Mas Tumenggung Wongsonegoro Hospital in Semarang, Indonesia. The identification process commenced with Gram staining and assessment of colony morphology preceded by antibiotic susceptibility testing utilizing the VITEK2 Compact systems. Results: The study findings revealed a notable prevalence of MDR infections. Fecal samples accounted for 29.15% of the samples analyzed, with 63.1% exhibiting MDR characteristics. Blood samples, representing 24.66% of the samples, displayed a concerning MDR rate of 83.6%. Similarly, urine samples (24.66%) showed a MDR rate of 50.9%, while sputum samples (10.76%) presented a striking MDR classification of 91.7%. Key MDR rates were identified in Escherichia coli (45.6%), Staphylococcus spp. (70.4%), Klebsiella pneumoniae (71.9%), Acinetobacter spp. (63.6%), and Pseudomonas aeruginosa (100%). The overall prevalence of MDR infections was calculated at 66.40%, with significant resistance observed towards ampicillin (over 80%) in gram‐negative bacteria and benzylpenicillin (over 90%) in gram‐positive bacteria, particularly Staphylococcus spp. Conclusion: The findings underscore the urgent need for effective strategies to combat MDR infections in healthcare settings, emphasizing enhanced antibiotic management, tailored treatment protocols, and a more holistic and systematically structured research strategy for neonatal units in Indonesia.
- Open Access
- 25 October 2025
- Published by Universitas Nahdlatul Ulama Surabaya in Indonesian Journal of Medical Laboratory Science and Technology
- Vol. 7 (2) , 88-97
Potential of ethanolic extracts from seed kernel Indonesian cultivars mangoes as an anti-multidrug-resistant (MDR) Escherichia coli
Escherichia coli is a type of bacteria that often found in wound infections. The use of antibiotics to treat these uncontrolled infections has resulted in the emergence of multi-drug resistant (MDR) strains of pathogenic bacteria. This rapid increase in MDR E. coli strains has led to significant morbidity and mortality in human populations. Consequently, the exploration of natural antibacterial agents is urgently needed. One promising resource is mango extract, which is recognised for its antibacterial properties and is obtained through solvent extraction using 96% ethanol. This study aimed to determine the antibacterial activity of seed extracts from seven different mango cultivars (Mangifera indica L.), against MDR E. coli. The study focused on determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) using dilution method. The concentrations examined for both MIC and MBC were 5, 10, 50, and 100 mg/mL. The results indicate that the mango seed extract exhibit significant antibacterial activity against MDR-E. coli., with the kweni cultivar showing the largest inhibition zone measuring 23.25 mm. The ethanol extract from the kweni seeds yielded the most favorable results, with an MIC value of ≥0.078 mg/mL and an MBC value that ranged from 1.25-10 mg/mL. In conclusion, mango seed extract, particularly from the kweni cultivar, has substantial potential to be developed as an effective antibacterial agent against MDR-E. coli.
- 25 October 2025
- Published by Universitas Nahdlatul Ulama Surabaya in Indonesian Journal of Medical Laboratory Science and Technology
- Vol. 7 (2) , 88-97
Open AccessPotential of ethanolic extracts from seed kernel Indonesian cultivars mangoes as an anti-multidrug-resistant (MDR) Escherichia coli
Escherichia coli is a type of bacteria that often found in wound infections. The use of antibiotics to treat these uncontrolled infections has resulted in the emergence of multi-drug resistant (MDR) strains of pathogenic bacteria. This rapid increase in MDR E. coli strains has led to significant morbidity and mortality in human populations. Consequently, the exploration of natural antibacterial agents is urgently needed. One promising resource is mango extract, which is recognised for its antibacterial properties and is obtained through solvent extraction using 96% ethanol. This study aimed to determine the antibacterial activity of seed extracts from seven different mango cultivars (Mangifera indica L.), against MDR E. coli. The study focused on determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) using dilution method. The concentrations examined for both MIC and MBC were 5, 10, 50, and 100 mg/mL. The results indicate that the mango seed extract exhibit significant antibacterial activity against MDR-E. coli., with the kweni cultivar showing the largest inhibition zone measuring 23.25 mm. The ethanol extract from the kweni seeds yielded the most favorable results, with an MIC value of ≥0.078 mg/mL and an MBC value that ranged from 1.25-10 mg/mL. In conclusion, mango seed extract, particularly from the kweni cultivar, has substantial potential to be developed as an effective antibacterial agent against MDR-E. coli.